Search
  • Within this site
AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Anti-Feline Proinsulin and Insulin Monoclonal Antibodies (10-line panel)


Detailed Technology Description

ApplicationsAnti-felineproinsulin antibodies useful for the study of feline metabolism and beta cellfunction. Possible applicability in the development of clinical diagnosticassays. Used in the development ELISA assays. Proinsulin is the precursor tothe prohormone, insulin, as well as the protein C-peptide made from beta cellsin the pancreas.  Mature insulin has 35fewer amino acids than proinsulin, 4 are removed altogether and the remaining31 form the C-peptide. The C-peptide is abstracted from the center of theproinsulin sequence and the two other ends (the B chain and A chain) remainconnected by disulfide bonds. The common spontaneous form of diabetes mellitusseen in cats closely resembles that of human type 2 diabetes. Similar riskfactors for the disease are seen in cats and people, such as age and obesity.Progression to type 2 diabetes is marked by increased resistance to insulinaction in peripheral tissues, especially skeletal muscle and adipose tissue,and decreased function of the ß-cell in insulin production and/or secretion.Early detection of ß-cell failure is critical in determining therapeutic routesto counter the disease. Recently, in human studies, it has been found that theearliest stages of ß-cell function loss can be observed as an increase in theproinsulin/insulin ratio in serum during fasting states. These antibodies whosespecificity for feline insulin, proinsulin, and C-peptide may prove useful inthe development of highly specific assays for determining serum concentrationsof intact feline proinsulin and insulin.


Country/Region

USA

For more information, please click Here
Business of IP Asia Forum
Desktop View